Abstract
APROP is an uncommon form of ROP. Untreated, eyes with APROP rapidly progress to retinal detachment and blindness. However, early recognition and prompt treatment often allow for effective management. This chapter updates the category of APROP with a more complete discussion including a detailed description of the features, a range of photographic examples, a discussion of more types of APROP, a treatment of diagnostic challenges, and recognition of earlier APROP in order to increase the opportunities for successful treatment. We also discuss the challenges and the alternatives for its practical treatment in order to improve outcomes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991–9. Review. PubMed PMID: 16009843.
Nissenkorn I, Kremer I, Gilad E, Cohen S, Ben-Sira I. ‘Rush’ type retinopathy of prematurity: report of three cases. Br J Ophthalmol. 1987 Jul;71(7):559–62. PubMed PMID: 3651370; PubMed Central PMCID: PMC1041226.
Palmer EA, Flynn JT, Hardy RJ, Phelps DL, Phillips CL, Schaffer DB, Tung B. Incidence and early course of retinopathy prematurity. The cryotherapy for retinopathy of prematurity cooperative group. Ophthalmology. 1991;98(11):1628–40.
Katz X, Kychenthal A, Dorta P. Zone I retinopathy of prematurity. J AAPOS. 2000;4(6):373–6.
Kychenthal A, Dorta P, Katz X. Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina. 2006;26(7 Suppl):S11–5.
Tasman W. Zone I retinopathy of prematurity. Arch Ophthalmol. 1985;103(11):1693–4. doi:10.1001/archopht.1985.0105011087032.
Shapiro MJ, Gieser JP, Warren KA, Resnik KI, Blair NP. Zone I retinopathy of prematurity. In: Shapiro MJ, Biglan AW, Miller M, editors. Retinopathy of prematurity. Proceedings of the international conference on retinopathy of prematurity. Chicago: Kugler Publications, 1993:149–55.
Shapiro MJ. Type 2 of Fulminate ROP. In: Kumar H, Shapiro MJ, Azad RV, editors. Apractical approach to retinopathy of prematurity screening and management. New Delhi: Malhotra Enterprises; 2001. p. 23–33.
Shah PK, Narendran V, Saravanan VR, Raghuram A, Chattopadhyay A, Kashyap M, Morris RJ, Vijay N, Raghuraman V, Shah V. Fulminate retinopathy of prematurity clinical characteristics and laser outcome. Indian J Ophthalmol. 2005;53(4):261–5. PubMed PMID: 16333175. Shah PK, Narendran V, Saravanan VR, Raghuram A, Chattopadhyay A, Kashyap M, Devraj S. Fulminate type of retinopathy of prematurity. Indian J Ophthalmol. 2004;52(4):319–20. PubMed PMID: 15693324.
Uemura Y, Tsukahara I, Nagata M, et al. Diagnostic and therapeutic criteria for retinopathy of prematurity. Committee’s Report Appointed by the Japanese Ministry of Health and Welfare. Tokyo, Japan: Japanese Ministry of Health and Welfare; 1974. Japan J. Ophthalmol. 1977;21:366–78.
Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, Holmström G. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol. 2013;91(2):170–5. doi:10.1111/j.1755-3768.2011.02351.x Epub 2012 Jan 23.
Vinekar A, Trese MT, Capone A Jr. Photographic screening for retinopathy of prematurity (PHOTO-ROP) cooperative group. Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol. 2008;145(3):548–55. doi:10.1016/j.ajo.2007.10.027. Epub 2008 Jan 22. PubMed PMID: 18207120.
Shah PK, Narendran V, Saravanan VR, Raghuram A, Chattopadhyay A, Kashyap M, Morris RJ, Vijay N, Raghuraman V, Shah V. Fulminate retinopathy of prematurity—clinical characteristics and laser outcome. Indian J Ophthalmol. 2005;53(4):261–5.
The Committee for Classification of Retinopathy of Prematurity. International classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130–4.
Woo R, Chan RV, Vinekar A, Chiang MF. Aggressive posterior retinopathy of prematurity: a pilot study of quantitative analysis of vascular features. Graefes Arch Clin Exp Ophthalmol. 2014 Nov 21. [Epub ahead of print] PubMed PMID: 25413261.
Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol. 2003;121:1684–94.
Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol. 1988;106:471–9.
Gunn DJ, Cartwright DW, Gole GA. Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity. Clin Experiment Ophthalmol. 2014;42(5):459–65. doi:10.1111/ceo.12280 Epub 2014 Jan 23.
Soh Y, Fujino T, Hatsukawa Y. Progression and timing of treatment of zone I retinopathy of prematurity. Am J Ophthalmol. 2008;146(3):369–74. doi:10.1016/j.ajo.2008.05.010 Epub 2008 Jul 7.
Schulenburg WE, Tsanaktsidis G. Variations in the morphology of retinopathy of prematurity in extremely low birthweight infants. Br J Ophthalmol. 2004;88(12):1500–3.
Drenser KA, Trese MT, Capone A Jr. Aggressive posterior retinopathy of prematurity. Retina. 2010;30(4 Suppl):S37–40. doi:10.1097/IAE.0b013e3181cb6151.
Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–15. doi:10.1056/NEJMoa1007374. PubMed PMID: 21323540; PubMed Central PMCID: PMC3119530.
Shah PK, Narendran V, Kalpana N. Aggressive posterior retinopathy of prematurity in large preterm babies in South India. Arch Dis Child Fetal Neonatal Ed. 2012;97(5):F371–5. doi:10.1136/fetalneonatal-2011-301121 Epub 2012 May 18.
Park SW, Jung HH, Heo H. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Acta Ophthalmol. 2014;92(8):810–3. doi:10.1111/aos.12461 Epub 2014 Jun 9.
Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000–6.
Sanghi G, Dogra MR, Das P, Vinekar A, Gupta A, Dutta S. Aggressive posterior retinopathy of prematurity in Asian Indian babies: spectrum of disease and outcome after laser treatment. Retina. 2009;29(9):1335–9. doi:10.1097/IAE.0b013e3181a68f3a.
Sanghi G, Dogra MR, Katoch D, Gupta A. Aggressive posterior retinopathy of prematurity in infants ≥ 1500 g birth weight. Indian J Ophthalmol. 2014;62(2):254–7. doi:10.4103/0301-4738.128639 PubMed PMID: 24618495.
Sanghi Gaurav, Dogra Mangat R, Katoch Deeksha, Gupta Amod. Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment despite confluent laser photocoagulation. Am J Ophthalmol. 2013;155(1):159–64.
Gunay M, Sekeroglu MA, Celik G, Gunay BO, Unlu C, Ovali F. Anterior segment ischemia following diode laser photocoagulation for aggressive posterior retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2014 Aug 9.
Suk KK, Berrocal AM, Murray TG, Rich R, Major JC, Hess D, Johnson RA. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 2010;47 Online:e1–4. doi:10.3928/01913913-20101217-06.
Nishina S, Yokoi T, Yokoi T, Kobayashi Y, Hiraoka M, Azuma N. Effect of early vitreous surgery for aggressive posterior retinopathy of prematurity detected by fundus fluorescein angiography. Ophthalmology. 2009;116(12):2442–7.
Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245(11):1727–30.
Ahn SJ, Kim JH, Kim SJ, Yu YS. Capillary-free vascularized retina in patients with aggressive posterior retinopathy of prematurity and late retinal capillary formation. Korean J Ophthalmol. 2013;27(2):109–15.
Wu WC, Kuo HK, Yeh PT, Yang CM, Lai CC, Chen SN. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Am J Ophthalmol. 2013;155(1):150–158.e1. doi:10.1016/j.ajo.2012.06.010. Epub 2012 Sep 8. PubMed PMID: 22967867.
Azad R, Dave V, Jalali S. Use of intravitreal anti-VEGF: retinopathy of prematurity surgeons’ in Hamlets’ dilemma. Ind J Ophthalmol. 2011;59:421–2.
Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98(2):F170–4. doi:10.1136/archdischild-2011-301148. Epub 2011 Dec 30. Review. PubMed PMID: 22209748.
Sato T, Wada K, Arahori H, Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153(2):327–333.e1. doi:10.1016/j.ajo.2011.07.005. PubMed PMID: 21930258.
Wu WC, Shih CP, Lien R, Wang NK, Chen YP, Chao AN, Chen KJ, Chen TL, Hwang YS, Lai CC. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina. 2016 Jul 27. [Epub ahead of print] PubMed.
Morin J, Luu TM, Superstein R, et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics. 2016;137(4):e20153218.
Lien R, Yu M-H, Hsu K-H, Liao P-J, Chen Y-P, Lai C-C, Wu W-C. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment.
Msall ME, Phelps DL, DiGaudio KM, Dobson V, Tung B, McClead RE, et al. On behalf of the cryotherapy for retinopathy of prematurity cooperative group. Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years. Pediatrics. 2000;106:998e1005.
Molloy CS, Anderson PJ, Anderson VA, Doyle LW. The long-term outcome of extremely preterm (<28 weeks’ gestational age) infants with and without severe retinopathy of prematurity. J Neuropsychol. 2015 Mar 24. doi:10.1111/jnp.12069. (Epub ahead of print) PubMed PMID: 25809467.
Cooke RWI, Hughes LF, Newsham D, Clark D. Ophthalmic impairments at 7 years of age in children born very preterm. Archs Dis Child Fetal Neonatal Ed. 2004;89:F249e53.
BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New Zealand Collaborative Group, Stenson BJ, Tarnow-Mordi WO, Darlow BA, Simes J, Juszczak E, Askie L, Battin M, Bowler U, Broadbent R, Cairns P, Davis PG, Deshpande S, Donoghoe M, Doyle L, Fleck BW, Ghadge A, Hague W,Halliday HL, Hewson M, King A, Kirby A, Marlow N, Meyer M, Morley C, Simmer K, Tin W, Wardle SP, Brocklehurst P. Oxygen saturation and outcomes in preterm infants. N Engl J Med. 2013;368(22):2094–104.
Phelps DL, Rosenbaum AL, Isenberg SJ, Leake RD, Dorey FJ. Tocopherol efficacy and safety for retinopathy of prematurity: a randomized, controlled, double-masked trial. Pediatrics. 1987;79(4):489–500.
Johnson L, Quinn GE, Abbasi S, Otis C, Goldstein D, Sacks L, Porat R, Fong E, Delivoria-Papadopoulos M, Peckham G, et al. Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: a controlled clinical trial. J Pediatr. 1989;114(5):827–38.
Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5. Arch Dis Child Fetal Neonatal Ed. 2013;98(4):F327–33.
Patel RD, Blair MP, Shapiro MJ, Lichtenstein SJ. Significant treatment failure with intravitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130(6):801–2. doi:10.1001/archophthalmol.2011.1802.
Wu W, Yeh P, Chen S, et al. Effects and complications of Bevacizumab use in patients with retinopathy of prematurity. A multicentre study in Taiwan. Ophthalmology. 2011;118:176–83.
Moran S, O’Keefe M, Hartnett C, Lanigan B, Murphy J, Donoghue V. Bevacizumab Versus Diode Laser in Stage 3 Posterior Retinopathy of Prematurity. Acta Ophthalmologica. 2014; e406–7. doi:10.1111/aos.12339.
Ittiara S, Blair MP, Shapiro MJ, Lichtenstein SJ. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab. J AAPOS. 2013;17(3):323–5. doi:10.1016/j.jaapos.2013.01.004.
Yokoi T, Hiraoka M, Miyamoto M, Yokoi T, Kobayashi Y, Nishina S, Azuma N. Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography. Ophthalmology. 2009;116(7):1377–82. doi:10.1016.
Buckle CE, Udawatta V, Straus CM. Now you see it, now you don’t: visual illusions in radiology. Radiographics. 2013;33(7):2087–102. doi:10.1148/rg.337125204. PubMed PMID: 24224600.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Appendix: Additional Aspects in the Development of APROP
Appendix: Additional Aspects in the Development of APROP
With detection of early stages of APROP, there are new questions about it natural history. In the era between CRYO-ROP and ETROP, we routinely counted stage 3 clock hours in order to determine presence of threshold ROP. While counting clock hours we also examined eyes at very high risk twice weekly. At that time, the only treatment was laser and eyes without macular development did not undergo subsequent development when it was spared. Initially, we watched a few cases hoping that the fovea would vascularize but it did not. The fastest progression that we observed in APROP neovascular proliferation was about 1 clock hour daily and my sense was that after a 2-week delay APROP was moderate. The neovascularization thickened but remained at the same distance from the optic nerve (Fig. 6.12). Therefore, our opinion based on anecdotal experience with a small number of observed cases, is that there is no ocular advantage in delay of treatment beyond the usual 48 h. We hope for better data in the future. However, we now have a nondestructive alternative to laser treatment. We have seen macular vascularization after treatment with bevacizumab (Fig. 6.14).
Occasionally, there are reports about posterior demarcation lines (stage 1) in APROP [52]. Since we have not seen photographs or an eye with this finding in APROP, it is unclear if this demarcation line is the same or different from the line in ICROP. This finding is not part of R-ICROP as we have understood it. However, in fact if CROP stage 1 is present but stage 2 and 3 do not develop then it meets the R-ICROP “does not progress through the classic stages 1 to 3”. This difference points to another area of definitional confusion in APROP, and, therefore, will need to be studied and clarified for the next review of APROP. In any case, the ICROP definition of stage 1 requires more than a halo in order to be called a demarcation line. In ICROP the “line is a thin but definite structure that separates the avascular retina anteriorly from the vascularized retina posteriorly.”
Although I have not seen the demarcation line discussed within APROP literature, I assume that my colleagues are reporting a classic stage 1 line. Nonetheless, it is important to be sure this is not a posterior halo, since color contrast is not sufficient to diagnose the presence of a line. Since the perceive color change may reflect a very interesting visual illusion identified by Ernst Mach. This produces an illusion of a line at the border of two shades of gray or color because of the center surround lateral inhibition in the retina. Mach bands are known as a cause for mistaken diagnosis in radiology [53]. This can be true in ROP at the vascular–avascular junction. Many photographs of APROP show a halo at the posterior edge of the avascular retina. Sometimes this changes with reduction of illumination and angle. To add to the confusion of terms in the literature, occasionally the term “demarcation” was used as a noun synonymously for the term “junction” (of the vascularized and avascular retina) [25] (Figs. 6.5, 6.9). Finally, we also wonder if there is yet another halo or demarcation line that may be the result of interstitial fibrous opacification or an edge reflecting marking changes in the choroidal development. Since the posterior retina is very difficult to depress and stereoscopic viewing through small pupil may be limited, the thickness of the stage 1 demarcation line structure cannot always be determined. Finally, we have the impression that the current Japanese ROP literature equates APROP with Japanese type 2 ROP (described and established before R-ICROP) and the two terminologies have evolved in a slightly different manner with communication outcomes that are occasionally at cross purposes (Fig. 6.3).
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Shapiro, M.J., Blair, M.P., Gonzalez, J.M.G. (2017). Aggressive Posterior Retinopathy of Prematurity (APROP). In: Kychenthal B., A., Dorta S., P. (eds) Retinopathy of Prematurity. Springer, Cham. https://doi.org/10.1007/978-3-319-52190-9_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-52190-9_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52188-6
Online ISBN: 978-3-319-52190-9
eBook Packages: MedicineMedicine (R0)